{
    "pmcid": "11554226",
    "qa_pairs": {
        "How does Tnb04-1 achieve broad neutralization against various sarbecoviruses?": [
            "By binding to a highly conserved hydrophobic pocket in the RBD, distinct from the ACE2 binding site.",
            "By targeting the spike protein's fusion peptide, preventing membrane fusion.",
            "By binding directly to the viral RNA, inhibiting replication.",
            "By interacting with the viral envelope protein, disrupting viral assembly."
        ],
        "What animal model was used to demonstrate the protective potential of Tnb04-1 against the Omicron XBB.1.5 subvariant?": [
            "Syrian hamster model.",
            "Mouse model.",
            "Ferret model.",
            "Rhesus macaque model."
        ],
        "What is the significance of the nanobody Tnb04-1 in the study on sarbecoviruses?": [
            "Tnb04-1 binds to a conserved epitope in the spike protein's RBD, maintaining neutralizing efficacy despite spike substitutions.",
            "Tnb04-1 targets the ACE2 binding site, preventing viral entry into host cells.",
            "Tnb04-1 is specific to the Omicron subvariant KP.3.1.1 and does not neutralize other variants.",
            "Tnb04-1 binds to a variable region of the spike protein, making it less effective against new variants."
        ],
        "What method was used to evaluate the inhibitory activity of Tnb04-1 against spike-mediated cell-cell fusion?": [
            "A dual-split protein (DSP) assay.",
            "A plaque reduction neutralization test (PRNT).",
            "An enzyme-linked immunosorbent assay (ELISA).",
            "A flow cytometry-based binding assay."
        ],
        "What was the IC50 of Tnb04-1 for the KP.3 variant in the neutralization assay?": [
            "0.002 \u03bcg/ml.",
            "0.02 \u03bcg/ml.",
            "0.2 \u03bcg/ml.",
            "0.0002 \u03bcg/ml."
        ]
    }
}